<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90663">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839253</url>
  </required_header>
  <id_info>
    <org_study_id>4-2012-0422</org_study_id>
    <nct_id>NCT01839253</nct_id>
  </id_info>
  <brief_title>The Effect of Antihypertensive Agents Concerning With Hemodynamics and Reduction of Anaesthetics in Orthognathic Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For those who receive hypotensive anesthesia in orthognathic surgeries, the investigators
      premedicate with anti-hypertensive agent so that it decreases the occurence of tachycardia
      and the rebound hypertension due to hypotensive anesthesia, enabling us to compare
      hemodynamic stability and reduction of anesthetic agents during the operation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>the influence of antihypertensive agents on hemodynamic stability</measure>
    <time_frame>From the beginning until the end of hypoetensive anesthesiaan expected average of 65 mins.(From manipulration of Mandible to maxilla)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total minutes when the MAP is lower than 55mmHg and higher than 65mmHg (min) , The time below 55 mmHg(min) , The total time above 65 mmHg (min) Total remifentanil amount, total NTG amount, total phenylephrine amount Arterial gas analysis 4 times after induction, at the start of manipulation of mandible, at the start of manipulation of maxilla, at the end of surgery.
Pr-operative and post-operative lab (Hb, Bun, Cr, OT, PT, Na, K) Intraoperative total fluid, total urine amount, total blood loss, transfusion amount.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of anaesthetics with control</measure>
    <time_frame>From the beginning until the end of hypoetensive anesthesia an expected average of 65 mins.(From manipulration of Mandible to maxilla)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total minutes when the MAP is lower than 55mmHg and higher than 65mmHg (min) , The time below 55 mmHg(min) , The total time above 65 mmHg (min) Total remifentanil amount, total NTG amount, total phenylephrine amount Arterial gas analysis 4 times after induction, at the start of manipulation of mandible, at the start of manipulation of maxilla, at the end of surgery.
Pr-operative and post-operative lab (Hb, Bun, Cr, OT, PT, Na, K) Intraoperative total fluid, total urine amount, total blood loss, transfusion amount.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Orthognathic Surgery</condition>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>none of antihypertensive agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>b-blocker(Atenolol)</intervention_name>
    <arm_group_label>Atenolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor(Enapril)</intervention_name>
    <arm_group_label>Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ASA class I-II

          2. obtaining written informed consent from the parents

          3. aged 18-29 years who were undergoing orthognathic surgery.

        Exclusion Criteria:

          1. Hypertension patients with anti-hypertensive agents

          2. chronic renal failure or End stage renal disease patients.

          3. renal artery stenosis history.

          4. Patients who are with medication due to systemic disease.

          5. symptomatic asthma

          6. Drug hyperactivity

          7. neurological or psychiatric illnesses

          8. mental retardation

          9. patients who can`t read the consent form due to illiterate or foreigner
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antihypertensive agents</keyword>
  <keyword>hemodynamic</keyword>
  <keyword>anesthetics reduction</keyword>
  <keyword>orthognathic surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
